Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 558Carcinoma, Non-Small-Cell Lung 514Prostatic Neoplasms 336Colorectal Neoplasms 273Neoplasms 269Multiple Myeloma 267Leukemia, Myeloid, Acute 225Squamous Cell Carcinoma of Head and Neck 217Lung Neoplasms 210Neoplasm Metastasis 205Carcinoma, Hepatocellular 198Melanoma 175Triple Negative Breast Neoplasms 174Pancreatic Neoplasms 171Recurrence 153Ovarian Neoplasms 152Lymphoma 142Glioblastoma 136Brain Neoplasms 134Sarcoma 131Carcinoma, Renal Cell 128Lymphoma, Large B-Cell, Diffuse 126Leukemia, Lymphocytic, Chronic, B-Cell 126Head and Neck Neoplasms 124Stomach Neoplasms 123Precursor Cell Lymphoblastic Leukemia-Lymphoma 110Rectal Neoplasms 109Myelodysplastic Syndromes 104Uterine Cervical Neoplasms 100Urinary Bladder Neoplasms 100

Interventions

amivantamab 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Hyaluronoglucosaminidase 1Cetuximab 1(225)Ac-DOTA-c(RGDyK) 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Locally Recurrent Skin Squamous Cell Carcinoma × 1 year × Clear all
NCT07042295 2026-06-03

Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

National Cancer Institute (NCI)

Phase 2 Suspended
86 enrolled

Locally Recurrent Skin Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡